Tags

Type your tag names separated by a space and hit enter

Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system.
Epileptic Disord. 2009 Dec; 11(4):301-8.ED

Abstract

This open study explored whether methylphenidate could be tolerated and effective in improving the quality of life (QOL) and attention deficit hyperactivity disorder (ADHD) symptoms of children with epilepsy and ADHD. Twenty-five subjects (aged 10.1 +/- 3.0 years) with ADHD and epilepsy were recruited at an outpatient clinic in Seoul, Korea. We used the Quality of Life in Childhood Epilepsy Questionnaire (QOLCE), ADHD rating scale (ARS) and clinical global impression (CGI) in this study. Osmotic-controlled release oral delivery system (OROS) methylphenidate, 1.0 +/- 0.4 mg/kg/day, was administered for 55.2 +/- 7.5 days. The QOL subscales including physical restriction (p = 0.005), self-esteem (p = 0.002), memory (p < 0.001), language (p = 0.005), other cognition (p < 0.001), social interaction (p = 0.002), behaviour (p < 0.001), general health (p = 0.002) and QOL (p < 0.001) were significantly increased and the ARS (p < 0.001) and CGI-Severity of illness scores (p < 0.001) were significantly reduced after medication. Although 60% of subjects had experienced adverse effects, most were tolerable and only two subjects withdrew from the study owing to unbearable adverse effects (anorexia and insomnia). Two subjects had seizure attacks during the study period without having to discontinue the trial drug. Despite limitations related to the small sample size and the open design of the present pilot study, our results suggest that OROS methylphenidate may be well tolerated and effective in reducing ADHD symptoms and improving QOL in this patient population.

Authors+Show Affiliations

Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. hiyoo@amc.seoul.krNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20007067

Citation

Yoo, Hanik K., et al. "Effect of Methylphenidate On the Quality of Life in Children With Epilepsy and Attention Deficit Hyperactivity Disorder: and Open-label Study Using an Osmotic-controlled Release Oral Delivery System." Epileptic Disorders : International Epilepsy Journal With Videotape, vol. 11, no. 4, 2009, pp. 301-8.
Yoo HK, Park S, Wang HR, et al. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system. Epileptic Disord. 2009;11(4):301-8.
Yoo, H. K., Park, S., Wang, H. R., Lee, J. S., Kim, K., Paik, K. W., Yum, M. S., & Ko, T. S. (2009). Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system. Epileptic Disorders : International Epilepsy Journal With Videotape, 11(4), 301-8. https://doi.org/10.1684/epd.2009.0278
Yoo HK, et al. Effect of Methylphenidate On the Quality of Life in Children With Epilepsy and Attention Deficit Hyperactivity Disorder: and Open-label Study Using an Osmotic-controlled Release Oral Delivery System. Epileptic Disord. 2009;11(4):301-8. PubMed PMID: 20007067.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system. AU - Yoo,Hanik K, AU - Park,Subin, AU - Wang,Hee-Ryung, AU - Lee,Joong Sun, AU - Kim,Kunwoo, AU - Paik,Kyoung-Won, AU - Yum,Mi Sun, AU - Ko,Tae-Sung, Y1 - 2009/12/15/ PY - 2009/12/17/entrez PY - 2009/12/17/pubmed PY - 2010/4/24/medline SP - 301 EP - 8 JF - Epileptic disorders : international epilepsy journal with videotape JO - Epileptic Disord VL - 11 IS - 4 N2 - This open study explored whether methylphenidate could be tolerated and effective in improving the quality of life (QOL) and attention deficit hyperactivity disorder (ADHD) symptoms of children with epilepsy and ADHD. Twenty-five subjects (aged 10.1 +/- 3.0 years) with ADHD and epilepsy were recruited at an outpatient clinic in Seoul, Korea. We used the Quality of Life in Childhood Epilepsy Questionnaire (QOLCE), ADHD rating scale (ARS) and clinical global impression (CGI) in this study. Osmotic-controlled release oral delivery system (OROS) methylphenidate, 1.0 +/- 0.4 mg/kg/day, was administered for 55.2 +/- 7.5 days. The QOL subscales including physical restriction (p = 0.005), self-esteem (p = 0.002), memory (p < 0.001), language (p = 0.005), other cognition (p < 0.001), social interaction (p = 0.002), behaviour (p < 0.001), general health (p = 0.002) and QOL (p < 0.001) were significantly increased and the ARS (p < 0.001) and CGI-Severity of illness scores (p < 0.001) were significantly reduced after medication. Although 60% of subjects had experienced adverse effects, most were tolerable and only two subjects withdrew from the study owing to unbearable adverse effects (anorexia and insomnia). Two subjects had seizure attacks during the study period without having to discontinue the trial drug. Despite limitations related to the small sample size and the open design of the present pilot study, our results suggest that OROS methylphenidate may be well tolerated and effective in reducing ADHD symptoms and improving QOL in this patient population. SN - 1294-9361 UR - https://www.unboundmedicine.com/medline/citation/20007067/Effect_of_methylphenidate_on_the_quality_of_life_in_children_with_epilepsy_and_attention_deficit_hyperactivity_disorder:_and_open_label_study_using_an_osmotic_controlled_release_oral_delivery_system_ L2 - http://www.jle.com/medline.md?issn=1294-9361&amp;vol=11&amp;iss=4&amp;page=301 DB - PRIME DP - Unbound Medicine ER -